Navigation Links
Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
Date:11/20/2007

"On both ethical and practical grounds, direct programming is superior to cloning as a means of obtaining patient-specific pluripotent stem cells."

WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Two major scientific papers published this week in Science and Cell unveil a proven way to generate patient-matched human pluripotent stem cells without human cloning, and without the use of human embryos or human or animal eggs. Research groups in Wisconsin and Japan have generated "induced pluripotent stem" (iPS) cells with the properties of human embryonic stem cells by direct reprogramming of adult cells.

These are the studies which prompted Ian Wilmut, creator of Dolly the sheep and one of the world's leading authorities on the cloning process Somatic Cell Nuclear Transfer (SCNT), to announce that he was abandoning SCNT to focus on reprogramming instead.

The following summary and analysis was produced by Maureen Condic, Ph.D., Associate Professor, Department of Neurobiology and Anatomy, University of Utah School of Medicine and Markus Grompe, M.D., Director, Oregon Stem Cell Center and Professor, Department of Molecular and Medical Genetics Oregon Health Sciences University (affiliations are for reference only). A fuller version of their analysis is available at the Do No Harm: The Coalition of Americans for Research Ethics website at http://www.stemcellresearch.org/statement/pptalkingpointsweb.pdf.

Summary of results and significance

Unlike embryonic stem cells, which are obtained by destroying live embryos, iPSCs are made directly from adult cells by adding a small number of factors to these cells in the laboratory. These factors remodel the mature cells and convert them into stem cells that are functionally identical to stem cells obtained from embryos. No human eggs are required and no human embryos are generated.

Adult cells are obtained from a simple skin biopsy, 1/10th inch in diameter and about as painful as a blood draw. One study was able to produce an average of 10 pluripotent stem cell lines from a single skin biopsy. This approach can be used to generate stem cell lines from patients with specific genetic diseases to better study these conditions, and to provide patient-specific stem cells for possible stem cell therapies.

Direct reprogramming of human cells is one of the most significant scientific findings of the last quarter century; more significant than cloning Dolly the sheep. Indeed, the scientist who originally cloned Dolly, Professor Ian Wilmut, recently stated that direct reprogramming is "extremely exciting and astonishing", a scientific approach he finds "100 times more interesting" than cloning--so much more interesting that he will abandon cloning research and pursue direct reprogramming instead.

The power of direct reprogramming is that, like cloning, it generates stem cells that are genetically identical to the patient who donated the adult cells. Reprogrammed cells would not be rejected by the patient's immune system if used for medical therapies. Unlike human cloning, which has thus far not been accomplished and remains only a theoretical possibility, iPSCs have been generated by two independent laboratories, making patient-specific pluripotent stem cells a reality today. Also unlike cloning, no eggs are needed for the iPS procedure and no human embryos are produced or destroyed, thus resolving major ethical and practical difficulties associated with the cloning procedure. Thus, on both ethical and practical grounds, direct programming is superior to cloning as a means of obtaining patient-specific pluripotent stem cells.

A fuller version of this analysis can be found online at http://www.stemcellresearch.org/statement/pptalkingpointsweb.pdf


'/>"/>
SOURCE Do No Harm: The Coalition of Americans for Research Ethics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
5. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
6. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
7. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
10. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
11. Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... In his newly appointed role ... May, Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s ... (WNB), and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, ...
(Date:6/20/2017)... West Hempstead, NY (PRWEB) , ... June 20, ... ... most experienced in the security systems industry has been selected as the partner ... , Amtrak is a passenger railroad service that provides medium- and long-distance intercity ...
(Date:6/20/2017)... ... 2017 , ... John D'Eri, CEO of Rising Tide Car Wash , ... during the Autism Society of America 's 49th annual conference to be ... Foundation (DJFF) was founded in 2002 as the nation's first autism organization focused ...
(Date:6/20/2017)... ... June 20, 2017 , ... MEDI+SIGN, ... like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. ... and expertise in healthcare will provide invaluable direction for the company,” says Andrew ...
(Date:6/20/2017)... ... , ... The law firm of Momkus McCluskey Roberts LLC congratulates ... DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the leadership role ... Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as ...
Breaking Medicine News(10 mins):